Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | NCF1 | P14598 | 1/20 | 0.59 |
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500755 | 0.92 | NPC1 (0.59) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30228591 | 0.90 | NPC1 (0.58) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5682765 | 0.90 | KDM4E (0.66) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30228475 | 0.90 | KDM4E (0.66) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2162844 | 0.89 | APP (0.57) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28992132 | 0.88 | PDGFRB (0.57) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28247825 | 0.88 | KDM4E (0.64) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30228533 | 0.88 | PDGFRB (0.57) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL483732 | 0.88 | MAPT (0.61) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL26613511 | 0.87 | KDM4E (0.72) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7084276-B2 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| US-7056931-B2 | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1395563-B1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | LILLY CO ELI (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1628961-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | Wyeth (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6962928-B2 | Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis | ELI LILLY AND COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1401446-B1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | LILLY CO ELI (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103973-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040215018-A1 | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods | WALLACE OWEN BRENDAN (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040132770-A1 | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen | ELI LILLY AND COMPANY | 2004-07-08 | — | — | US | disclosed |
| EP-1401446-A1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1395563-A1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094268-A1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094788-A1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132770-A1 | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen | ESR2, ESR1, GPER1 | KDM4E 448/4885NPC1 1803/4885RAB9A 1993/4885 |
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | KDM4E 638/4885NPC1 1622/4885RAB9A 2360/4885 |
| US-20040215018-A1 | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods | CYP19A1, ESR2, NR5A1 | KDM4E 346/4885NPC1 1277/4885RAB9A 3535/4885 |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | KDM4E 638/4885NPC1 1622/4885RAB9A 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.